China Huijin Biotech-B (02627) received a subscription rate of 4007.64 times for its public offering in Hong Kong at a price of HK$12.9 per share.

ChinaBiologic Products Holdings, Inc. (02627) announced the results of its distribution, with a total of 33.4426 million shares sold globally. The Hong Kong public offering accounted for 11.95%, while the international offering accounted for 88.05%. The final offering price was HK$12.9 per share, raising approximately HK$383 million from the global offering. Trading of H shares is expected to begin on Monday, August 11, 2025 at 9:00 a.m. Hong Kong time. The Hong Kong public offering was oversubscribed 4007.64 times, while the international offering was oversubscribed 0.99 times.